AstraZeneca has scored a major trial victory after its Farxiga (dapagliflozin) became the first drug in its class to show efficacy in heart failure, in patients with or without type-2 diabetes.

AstraZeneca is still stinging after its SGLT2 diabetes drug Farxiga was waved off by the FDA in Type 1 disease. But here's something that could ease the pain: New outcomes data showing Farxiga cut ...

When SGLT2 med Farxiga scored a major cardiovascular outcomes win last month, AstraZeneca touted the drug’s trial results as a game changer for the market. Turns out the FDA likes those results, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Phase III DAPA-MI trial will evaluate FARXIGA as a treatment to reduce mortality and the risk of heart failure following a heart attack WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca has been granted ...

FARXIGA is the first SGLT2 inhibitor proven to significantly reduce the risk of cardiovascular death and hospitalization for heart failure WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s FARXIGA® ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s FARXIGA ® (dapagliflozin) has been approved by the US Food and Drug Administration (FDA) to improve glycemic control in pediatric patients with type-2 ...

The FDA has fast-tracked AstraZeneca’s Farxiga in a potential new use, to delay progression of renal failure and prevent cardiovascular death and renal death in patients with chronic kidney disease ...

AstraZeneca has moved a step close to a chronic heart failure claim for its diabetes drug Farxiga after reporting positive results in a phase 3 trial. The phase 3 DAPA-HF trial has shown that SGLT2 ...

AstraZeneca’s Farxiga (dapagliflozin) has scored fast track designation (FTD) from the FDA in the US, continuing its upward trajectory in heart failure. Earlier this month, AZ revealed the results of ...